Professional Marketing briefs

Share this article:
Shire CEO Angus Russell, seeking to stem concerns about an OIG investigation of his firm's ADHD sales and marketing practices, said such inquiries have “almost become standard practice” in this industry and that “at this stage, it's a general inquiry.” Shire revealed that it had been subpoenaed for information on Adderall XR, Daytrana and Vyvanse promotion.

Eli Lilly is trimming its osteoporosis, diabetes and neurosciences sales forces by a total of 191 jobs as part of a restructuring plan announced in September, Indianapolis Business Journal reports. The company intends to lay off 5,500 by 2011 in an effort to soften the blow when Zyprexa, which has $4.7 billion in global sales, goes off patent the same year.

Warner Chilcott completed its $3.1 billion acquisition of P&G's global branded prescription pharmaceuticals unit, securing a 1,200-person sales force and a portfolio worth $2.3 billion in annual revenue. The company, based in Ireland, now markets such former P&G products as blockbuster brand Actonel (risedronate) for osteoporosis and colitis drug Asacol (mesalamine).


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters